证券日报网讯1月7日，爱博医疗在互动平台回答投资者提问时表示，公司通过产业基金对外投资，主要 围绕产业链布局，服务于公司长期发展战略。公司将多措并举提升价值，切实回报股东。 ...

证券日报网讯1月7日，新华医疗（600587）在互动平台回答投资者提问时表示，采购国产优先政策有望 提升中标率与市场份额，具体受益金额受多重因素影响，公司将积极把握政策机遇，扩大市场份额。 ...

证券日报网讯 1月7日，新华医疗在互动平台回答投资者提问时表示，公司本次对子公司新华医疗康复 产业（西安）有限公司增资6000万元主要用于子公司康复器械整体业务的研发、生产及营运资金补充。 （编辑 任世碧） ...

证券日报网讯1月7日，蓝帆医疗（002382）发布公告称，公司将于2026年1月26日14：00召开2026年第 一次临时股东会。 ...

证券日报网讯 1月7日，瑞迈特（301367）在互动平台回答投资者提问时表示，截至目前，公司呼吸机 产品仍纳入国家相关补贴政策的适用范围。 ...

Core Insights - China is enhancing support for innovative drugs with new mechanisms and targets across the entire chain of communication, clinical trials, registration, and review processes to facilitate "China's first launch" of innovative drugs [1][2] - By 2025, there is an expectation for a significant increase in the market launch of urgently needed clinical products in the pharmaceutical and medical device sectors [1] Group 1: Pharmaceutical Sector - In 2022, the National Medical Products Administration (NMPA) approved a total of 4,087 drug registration applications, including 76 innovative drugs, marking a historical high [1] - The time gap for domestic and international drug listings has been reduced, with 59 foreign new drugs receiving temporary import approval [1] - A total of 138 children's drugs were approved, and 48 rare disease drugs were granted temporary import approval, addressing medication gaps for special populations [1] Group 2: Medical Device Sector - The NMPA approved 3,402 medical device products in 2022, including 76 innovative medical devices, achieving a new record [1] - The medical device innovation ecosystem is continuously improving, supporting industry upgrades [1][2] - In 2026, the NMPA plans to expedite the market launch of high-end medical devices and allocate more review resources to urgently needed innovative devices and those for rare disease prevention [2] Group 3: Future Initiatives - The NMPA will implement a drug trial data protection system and establish market exclusivity for children's and rare disease medications [2] - There will be a focus on optimizing the review and approval measures for cell and gene therapy drugs [2] - The establishment of a national standardized technical working group for intelligent frontier medical devices is planned to advance standard formulation in key areas such as brain-machine interfaces [2]

精锋医疗-B(02675)将于2026年1月8日(星期四)在香港挂牌。截至收盘，利弗莫尔证券暗盘交易显示报价59.6港元，较招股价43.24港元上涨 37.84%，每手100股，不计手续费，每手赚1636港元。 59.250 -(- -) 21.780 -49.63% 4.96万 59.200 |0股额:0 - -(- -) 를 - -(- -) 59.150 16:15 17:30 18:30 18:00 1分 २२ स्त्र स्थ 日K 买盘十档 卖盘十档 50.79% 49.21% 立即卖出 立即买入 • 行情来源: 利弗莫尔证券 • ...

Group 1 - The core point of the news is the recognition of Dong Fan, Chairman and President of Jianfan Group, as the "National Excellent Private Entrepreneur Caring for Employees," making Jianfan Group the only enterprise in Guangdong Province to receive this honor [1][3][5] - The award aims to acknowledge private entrepreneurs who have made significant contributions to promoting high-quality employment, fulfilling social responsibilities, and creating harmonious labor relations [5] - Jianfan Group emphasizes a people-oriented approach, focusing on employee care and shared development outcomes, which has led to significant economic and social benefits, including the global promotion of innovative blood adsorption technology [6][8] Group 2 - Under Dong Fan's leadership, Jianfan Group has implemented comprehensive labor contracts and social insurance coverage, ensuring steady wage growth for employees [8] - The company has established a holistic support system for employees, including facilities like "Union Love Mom's Room" and "Health Room," to provide a warm and healthy working environment [8] - Jianfan Group has received multiple honors for its efforts in building harmonious labor relations, including "National Model Worker Home" and "National Harmonious Labor Relations Innovation Demonstration Enterprise" [8]

Core Viewpoint - The company, Pumen Technology (688389.SH), clarified that its main business does not include the brain engineering sector, focusing instead on in vitro diagnostics, clinical medicine, skin aesthetics, and consumer health [2] Summary by Relevant Categories Business Scope - The company's primary operations encompass in vitro diagnostics, clinical medicine, skin aesthetics, and consumer health [2] Investor Interaction - An investor inquired whether the company's medical device business falls under the brain engineering sector, to which the company responded that it currently does not engage in this area [2]

Core Viewpoint - The national drug supervision work conference emphasized key tasks for 2026 to ensure a good start for the "14th Five-Year Plan," focusing on drug safety, industry development, legal standards, and modernization of drug regulation [1] Group 1: Drug Safety - The conference highlighted the need to ensure high-level drug safety by improving the drug safety responsibility system and enhancing clinical trial supervision [1] - There will be increased inspection and sampling efforts on key varieties, especially those selected in centralized procurement [1] - The initiative includes a "clean source" action in drug distribution and strengthened regulation of online sales to maintain drug safety standards [1] Group 2: Industry Development - The conference aims to support the pharmaceutical industry in improving quality and efficiency through comprehensive reform of drug regulation [1] - It emphasizes early intervention and tailored strategies for key products, promoting innovation in drug research and development [1] - The focus also includes supporting the self-reliance of high-level medical devices and fostering the growth of the beautiful economy [1] Group 3: Legal Framework - Continuous improvement of the drug regulation legal framework is a priority, including enhancing the authority and credibility of administrative law enforcement [1] - There will be increased legal education efforts directed at enterprises and grassroots levels to solidify the legal foundation of drug regulation [1] Group 4: Modernization of Drug Regulation - The conference calls for high-quality development of the "14th Five-Year" drug planning and the promotion of integrated national drug regulation [1] - Strengthening the regulatory talent pool and technical support capabilities is essential, along with advancing regulatory information technology and scientific research applications [1] - The initiative aims to enhance China's international influence in drug regulation and participate actively in global drug safety governance [1]